secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2024-05-28T23:59:59+00:00
Accession:  0001171843-24-003136
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Therapeutics adds two directors, announces $40M buyback under Caligan deal
--------------------------------------------------------------------------------

- Appointed Joseph Capper (MIMEDX CEO) and William Jellison (former Stryker CFO) to Board; board expands to 10 then reduces to 9 after 2024 annual meeting.
- Authorized $40M share repurchase program: $15M via 10b5-1 by June 2025, remainder open market through June 2026, replacing April 2023 program.
- Caligan agrees to standstill, voting commitments, and other provisions under cooperation agreement.
- Reaffirmed 2024 adjusted EBITDA guidance of $25-30M, up >75% YoY at midpoint.
- New directors join Capital Allocation Committee; no prior relationships or transactions disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184324003136/0001171843-24-003136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184324003136/f8k_052824.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-003136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer